Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study (Q84491268)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21723597%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21723597%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study (English)

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2011.06.019

6 December 2024

1 reference

3

Cezary Szczylik

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21723597%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1

Lubomir Bodnar

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21723597%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

Maria Górnas

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21723597%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21723597

6 December 2024

publication date

1 July 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21723597%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

6 February 2020

https://api.elsevier.com/content/article/PII:S0090825811004860?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2011.06.019

https://api.elsevier.com/content/article/PII:S0090825811004860?httpAccept=text/plain

6 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.YGYNO.2011.06.019

6 December 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21723597%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

123

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21723597%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21723597%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

33-36

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21723597%20AND%20SRC:MED&resulttype=core&format=json

Cancer burden in the year 2000. The global picture

6 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

7 January 2021

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Vascular endothelial growth factor expression in early stage ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Sorafenib in advanced clear-cell renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Sorafenib in advanced hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Sample Size Estimation: How Many Individuals Should Be Studied?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Salvage therapy with topotecan in heavily pretreated ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.06.019

7 January 2021

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21723597%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference